Research interests
Bradley M. Wertheim authored the 2022 editorial “New Tricks for an Old Drug: Prostacyclins and Right Ventricular Contractility in Pulmonary Arterial Hypertension.”[11]
2022
BW
Bradley Wertheim is a member of the Harvard Medical School faculty.
Current relationship
Bradley Wertheim is a Harvard Medical School faculty physician and pulmonary vascular specialist whose work connects pulmonary arterial hypertension (PAH) care, cardiopulmonary physiology, and vascular biology. He studied biochemistry at Lafayette College, earned his M.D. from Harvard Medical School in 2011, completed internal medicine training at Massachusetts General Hospital through 2014, and pursued pulmonary and critical care fellowship training at Brigham and Women’s Hospital from 2014 to 2017. He was the first physician selected for Brigham’s Burke Advanced Fellowship in Pulmonary Heart Disease and founded the Rheumatic Pulmonary Vascular Disease Clinic. His research examines PAH biology and treatment strategies, including vascular metabolism, endothelial fibrosis, and targeted therapies. He trains fellows and residents at Brigham and Women’s Hospital and participated in a 2023 PVRI Community Call on PAH-related pregnancy outcomes and metabolic reprogramming.
Each topic is linked to its supporting source in Sources.
Training includes Bradley Wertheim completed pulmonary disease and critical care medicine fellowship training at Mass General Brigham/Brigham and Women's Hospital from 2014 to 2017., Bradley Wertheim completed a post-doctoral fellowship at Brigham and Women's Hospital in 2017., Bradley Wertheim completed an internal medicine residency at Massachusetts General Hospital from 2011 to 2014., and Bradley Wertheim completed an internal medicine internship at Massachusetts General Hospital in 2012., plus 4 more records.
Explore education and trainingAs of 2023
2022
As of 2017
Bradley M. Wertheim authored the 2022 editorial “New Tricks for an Old Drug: Prostacyclins and Right Ventricular Contractility in Pulmonary Arterial Hypertension.”[11]
2022
Bradley Wertheim discussed maternal outcomes among pregnant women with congenital heart disease-associated pulmonary hypertension.[10]
2023
Bradley Wertheim discussed proline and glucose metabolic reprogramming in pulmonary arterial hypertension.[10]
2023
Bradley Wertheim studies pulmonary arterial hypertension biology to identify treatment strategies.[9]
Grant support listed for Bradley Wertheim includes a 2020-2025 project on ubiquitination and endothelial fibrosis in early pulmonary arterial hypertension.[12]
2020 to 2025
Grant support listed for Bradley Wertheim includes a 2024-2026 project on endothelial proline utilization in pulmonary arterial hypertension.[12]
2024 to 2026
Grant support listed for Bradley Wertheim includes a 2025-2030 project on endothelial inflammation, Src kinase dysregulation, and fibrosis in early pulmonary arterial hypertension.[12]
2025 to 2030